Therapy News and Research

RSS

Cord Blood America shares web site post on Thanksgiving Day

On this day before Thanksgiving, a day when our entire nation gives thanks for its blessing, Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, would like to share with its investors a post from its web site by Dr. Geoffrey O'Neill, CBAI Vice President, Operations.

24 Nov 2010

SIRS-Lab, Pfizer collaborate to improve patients’ outcome with sepsis

SIRS-Lab GmbH, a molecular diagnostics company based in Jena, Germany, and Pfizer Pharma GmbH, headquartered in Berlin, have announced a collaboration in the field of sepsis.

24 Nov 2010

UNAIDS 2010 report documents significant progress in reducing pediatric HIV infection

The just-released UNAIDS 2010 report on the global AIDS epidemic reflects that there is increased momentum to eliminate pediatric HIV and AIDS worldwide, and documents significant progress in increasing access to services to prevent mother-to-child transmission (PMTCT) of HIV, reducing new infections in children, and providing treatment for children, mothers, and families living with the virus.

24 Nov 2010

iPrEx study: PrEP reduces HIV infection risk among gay, bisexual men

A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men.

24 Nov 2010

Provectus reports progress in PV-10 program for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.

24 Nov 2010

Pathological gamblers more likely to commit suicide

Pathological gamblers are risking more than their money, they are also three times more likely to commit suicide than non-betters. A new Montreal inter-university study has shown these gamblers are also plagued by personality disorders. These findings, published in a recent issue of the Psychology of Addictive Behaviors, may have implications for developing improved targeted suicide prevention programs.

24 Nov 2010

Researchers find link between acrolein and multiple sclerosis

Researchers have found evidence that an environmental pollutant may play an important role in causing multiple sclerosis and that a hypertension drug might be used to treat the disease.

24 Nov 2010

New genomic approach to evaluate suspicious thyroid nodules

Doctors at the University of Colorado School of Medicine were concerned recently when they found a nodule in the thyroid of a 64-year-old Colorado man. They extracted cells from the nodule, hoping to determine whether the man had cancer. But the biopsy results were inconclusive.

24 Nov 2010

CONRAD congratulates Global iPrEx study team for HIV prevention trial

CONRAD is pleased to join in congratulating the Global iPrEx study team for their successful trial of oral tenofovir (TDF) with emtricitabine (FTC) for HIV prevention.

24 Nov 2010

Disrupting estrogen pathway can halt expansion of breast cancer stem cells: Research

Breast cancer stem cells (CSCs), the aggressive cells thought to be resistant to current anti-cancer therapies and which promote metastasis, are stimulated by estrogen via a pathway that mirrors normal stem cell development.

23 Nov 2010

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.

23 Nov 2010

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C.

23 Nov 2010

Budapest meeting to highlight discrepancies in using implantable devices among European countries

Even though the use of implantable devices for the treatment of heart failure and heart rhythm disturbances has increased enormously in Europe in recent years, there still remain large differences between countries. Indeed, a report last year in the European Journal of Heart Failure found that there is an underuse of devices in many of the European countries surveyed. This is especially so in the emerging economies of Eastern Europe.

23 Nov 2010

Racial disparities in risk and survival among children with neuroblastoma: Study

Black, Asian, and Native American children are more likely than white and Hispanic children to die after being treated for neuroblastoma, according to new research on the pediatric cancer. The study, of more than 3,500 patients with the disease, is the largest ever to look at racial disparities in risk and survival for the most common solid cancer found in young children.

23 Nov 2010

Implanted devices to treat cardiac dysfunction show success in real world use

Implanted devices that treat cardiac dysfunction in heart failure patients are as successful in "real world" use as they are in controlled clinical trial settings, according to a large new study reported in Circulation: Journal of the American Heart Association.

23 Nov 2010

Landmark comparative study supports more frequent hemodialysis

NxStage® Medical, Inc., a leading manufacturer of innovative dialysis products, today commented on the just- released findings of the Frequent Hemodialysis Network (FHN) Daily Trial that compared in-center hemodialysis administered under a three times per week schedule ("conventional dialysis") versus six shorter sessions per week ("short daily dialysis").

23 Nov 2010

Researchers highlight importance of motivating people to seek HIV testing

HIV infected patients whose treatment is delayed not only become sicker than those treated earlier, but also require tens of thousands of dollars more in care over the first several years of their treatment.

23 Nov 2010

Aggressive surgery for brain tumors increases survival in children

A new Mayo Clinic study found that children with low-grade brain tumors (gliomas) who undergo aggressive surgery to completely remove the tumor have an increased chance of overall survival. If complete removal is not possible, adding radiation therapy to a less complete surgery provides patients with the same outcomes as a complete removal.

23 Nov 2010

ADA systematic review provides nutrition practice guidelines to support people with diabetes

Proper nutrition therapy is essential for the successful management of type 1 and type 2 diabetes and registered dietitians (RDs) can play a key role as part of the health care team.

23 Nov 2010

CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

23 Nov 2010